Holen Sie sich die Stockscreener-App
9.18
3.06%
-0.30
Schlusskurs vom Vortag:
$9.48
Offen:
$9.61
24-Stunden-Volumen:
1.55M
Relative Volume:
0.49
Marktkapitalisierung:
$1.47B
Einnahmen:
$68.56M
Nettoeinkommen (Verlust:
$-437.99M
KGV:
-2.9015
EPS:
-3.1639
Netto-Cashflow:
$-396.61M
1W Leistung:
-3.77%
1M Leistung:
+23.02%
6M Leistung:
+83.80%
1J Leistung:
+31.28%
1-Tages-Spanne:
$9.12
$9.73
1-Wochen-Bereich:
$9.12
$10.29
52-Wochen-Spanne:
$4.155
$10.94
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.185 | 1.52B | 68.56M | -437.99M | -396.61M | -3.1639 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.52 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.24 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.10 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.69 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.42 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Eingeleitet | Evercore ISI | Outperform |
| 2025-08-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology Stock Pre-Market (+0.2%): Ahead of Leerink Conference Presentation - Trefis
Biggest stock movers Tuesday: HIMS, VIR, CLVT, and more - MSN
VIR-5500 Phase 1 trial yields positive data in prostate cancer, Vir Biotechnology asserts - Traders Union
Vanguard Group Inc. Lowers Stock Position in Vir Biotechnology, Inc. $VIR - MarketBeat
HC Wainwright Brokers Boost Earnings Estimates for VIR - MarketBeat
Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? - Stocktwits
Vir Biotechnology Names CEO Marianne De Backer as President - The Globe and Mail
According to the latest filing disclosed by the U.S. Securities and Exchange Commission (SEC), biotechnology company Vir Biotechnology, Inc. has announced a significant personnel appointment. - Bitget
Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026SEC Filing - TradingView
Vir Biotechnology appoints Marianne De Backer as president in addition to CEO on March 4, 2026SEC filing - marketscreener.com
Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
VIR: HC Wainwright & Co. Raises Price Target to $20, Maintains B - GuruFocus
Assessing Vir Biotechnology (VIR) Valuation After Astellas Alliance And VIR-5500 Phase 1 Update - simplywall.st
Vir Biotechnology, Inc. (VIR) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
VIR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insider Sell: Vicki Sato Sells 22,000 Shares of Vir Biotechnology Inc (VIR) - GuruFocus
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares - MarketBeat
22,000 Vir Biotechnology (VIR) shares sold under 10b5-1 plan - Stock Titan
VIR (NASDAQ: VIR) files Form 144 for 88,000 pre-IPO shares - Stock Titan
Vir Biotechnology closes $172.5 million public offering of common stock - Investing.com South Africa
Vir Biotechnology Raises Capital Through Public Stock Offering - TipRanks
Vir Biotechnology closes $172.5 million public offering of common stock By Investing.com - Investing.com UK
Vir Biotechnology completes $172.5M follow-on offering, issues 20.29M shares - TradingView
[8-K] Vir Biotechnology, Inc. Reports Material Event | VIR SEC FilingForm 8-K - Stock Titan
Vir Biotechnology Astellas Deal Puts VIR-5500 And Valuation In Focus - Yahoo Finance
Vir Biotechnology (NASDAQ:VIR) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Watch Vir Bio CEO on Cancer Treatment Progress, Potential Deals - Bloomberg
Why Vir Biotechnology (VIR) Is Up 20.2% After Astellas Deal And $150 Million Equity Raise - simplywall.st
Leerink Maintains Outperform on Vir Biotechnology, Inc. (VIR) Feb 2026 - Meyka
Insider Selling: Vir Biotechnology (NASDAQ:VIR) CFO Sells 1,634 Shares of Stock - MarketBeat
Brent Sabatini Sells 1,430 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Mark Eisner Sells 1,616 Shares of Vir Biotechnology (NASDAQ:VIR) Stock - MarketBeat
Vir Biotechnology (NASDAQ:VIR) EVP Verneuil Vanina De Sells 3,117 Shares - MarketBeat
Vir Biotechnology Announces Significant Common Stock Offering - TipRanks
Vir Biotechnology prices $150M stock offering at $8.50/share By Investing.com - Investing.com Australia
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 42,377 Shares - MarketBeat
Vir Biotechnology (NASDAQ:VIR) CEO Backer Marianne De Sells 14,762 Shares - MarketBeat
Vir Biotechnology (NASDAQ: VIR) plans $141.1M stock sale - Stock Titan
Vir Biotechnology (VIR) to Sell 17.65M Shares; Astellas Collaboration Disclosed - Stock Titan
Vir Biotechnology (VIR) director Sato exercises options and sells 42,377 shares - Stock Titan
[Form 4] Vir Biotechnology, Inc. Insider Trading Activity - Stock Titan
Vir Biotechnology (VIR) CFO executes automatic 10b5-1 share sale for taxes - Stock Titan
Vir Biotechnology (VIR) CMO reports 3,505-share Rule 10b5-1 stock sale - Stock Titan
Vir Biotechnology (VIR) EVP’s 10b5-1, tax-driven sales total 16,817 shares - Stock Titan
Vir Biotechnology to Participate in Upcoming Investor Conferences - Business Wire
Leerink raises Vir Biotechnology stock price target on partnership - Investing.com
Latham & Watkins Advises on Vir Biotechnology’s US$150 Million Public Offering of Common Stock - Latham & Watkins LLP
Vir Biotechnology (NASDAQ:VIR) Shares Gap DownShould You Sell? - MarketBeat
Vir Biotechnology (VIR) Earnings Call Transcript - AOL.com
Vir Biotechnology Prices $150 Mln Public Offering At $8.50 Per Share, Stock Down - Nasdaq
Vir Biotechnology stock tumbles on discounted share offering - Investing.com
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):